John E. Morley, M.D.
During the last three years, Dr. Morley has received grant/research support from Vivus, Merck & Co., Upjohn, B.Braun McGaw, Bayer Corp and Nestec, Ltd. He has also served on the Speakers' Bureau for LXN, Organon, Ross, Pharmacia & Upjohn, Glaxo Wellcome, Hoechst Marion Roussel, Searle, Merck & Co., Roche, Bristol-Myers Squibb, Novartis, Pratt, B. Braun McGaw, Pfizer and Parke-Davis.
Release Date: 05/07/2002
Upon completion of this Cyberounds®, you should be able to:
Describe why beta-cell dysfunction still remains the primary genetic lesion in non-insulin dependent diabetes mellitus
Recognize that physicians often fail to recognize and treat diabetes in older persons
Understand the potential for associated lactic acidosis in the elderly with metformin
Discuss the role of the newer oral agents in the management of diabetes mellitus in the elderly.